Dr. Liudmila Cebotaru received a RN degree in 1990 from the Medical College in Balti, Moldova. She continued her medical training by obtaining an MD degree in 1996 from 'Carol Davila' Medical School, University of Bucharest, Romania and then obtained further training in the areas of pathology and medicine. She also successfully achieved a JD degree in 1997 from the University of Bucharest School Of Law, Romania. Her interest in law continued in the US, where she later received a Master's Degree in US Law (LL.M) in 2012 from the University of Baltimore. Although Dr. Cebotaru came to the US with a solid background in clinical medicine and law, she had a strong desire to pursue a career in science. With this in mind, she was awarded a post-doctoral fellowship in 2001 in the Department of Medicine and in the Department of Physiology. Her research included studies on Gene Therapy in Cystic Fibrosis and understanding the folding defect in proteins associated with genetic diseases particularly those for which there is no long-term treatment. She discovered that the previously manufactured âˆ†264-CFTR functions to correct Î”F508-CFTR through transcomplementation. Dr. Cebotaru has risen through the ranks, at Johns Hopkins, first as a Research Associate, then an Instructor,Assistant Professor and Associate Professor. Dr. Cebotaru leads the CF gene therapy program at Hopkins with an NIH funded R01 for preclinical and clinical development of Adeno-associated viral gene therapy. She strongly believes that by understanding the mechanism of the disease processes at a basic level, we can devise strategies to correct or at least, bypass defective proteins and restore function. Her interests extend to understanding the folding defect in Class II mutations, and rescuing function with CFTR correctors. She is currently applying her expertise to understanding the impact of conduction mutants on bicarbonate movement through CFTR and its role in the CF phenotype. She has 42 publications, has successfully mentored students, post-docs and faculty, and has spoken extensively both within and outside of the US. She is recognized nationally and international for her contributions to treat CF with Gene Therapy and application of correcting the primary defect in proteins associated with genetic diseases.